Legislation introduced to Parliament on the final sitting day of 2016 will enable faster access to certain new medicines for Australian patients and help to cut unnecessary red tape for industry too.
The Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 was introduced by Health Minister Sussan Ley, and is the first legislative step toward the full implementation of the Medicines and Medical Devices Review.
The bill includes measures which support the introduction of new expedited pathways for the marketing approval of certain medicines and medical devices, by providing a regulation-making power to set out the details of the new pathways for priority review, Ms Ley noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze